Alivus LifeQ1 FY27
Alivus Life Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,349P/E: 26.7Market Cap: ₹16.6K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 2
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →Alivus Life Sciences expects revenue growth of 10% to 12% in FY '27, with stronger growth skewed towards the second half of the year.
- →Non-GPL business is driving strong growth, with a 26.5% year-on-year increase in Q1 FY '27, supported by a robust product pipeline and recent launches.
- →CDMO business is anticipated to accelerate in H2 FY '27 and beyond as new projects commercialize, contributing to faster growth than the overall business.
- →The company is working on 7 active CDMO projects and anticipates closing 2 new CDMO contracts in early H2 FY '27.
- →Pipeline of 28-29 new high-potent API products being commercialized gradually, with significant launches expected from FY '28 onward.
- →Volume growth in non-GPL business is about 21-22%, with price declines around 1-2%.
- →Capacity expansions at Dahej and Ankleshwar as well as Solapur (operational by early Q3 FY '27) will support double-digit growth in FY '27 and FY '28.
Margin guidance
Category 2- →Revenue Growth: Alivus is guiding for 10% to 12% revenue growth in FY '27, with growth skewed towards the second half of the year.
- →Margin Outlook: EBITDA margins are expected to be sustained in the 30% to 32% range, with potential upside to 34% contingent on stable conditions.
- →CDMO Business: Expected to grow faster than the overall business with contributions from 7 active projects; 2 new CDMO contracts anticipated in early H2 FY '27.
- →R&D Investment: R&D spend expected to stabilize at around 4% of revenue, primarily driving API pipeline growth and supporting margin improvements.
- →Profitability: PAT margins have improved and are expected to remain strong; margin growth driven by new API launches and operational efficiencies.
- →Capacity Utilization: Existing facilities and expansions at Ankleshwar and Dahej support double-digit growth; Solapur facility operational by Q3 FY '27 will boost future capacity.
- →Long-Term Pipeline: Strong launch momentum in high-potent APIs projected to sustain growth and profitability over the next 4-5 years.
3 more insights locked — sign up free to unlock
Fundraise plans
- →There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
- →The company reported being a debt-free entity with strong cash and cash equivalents of INR880 crores as of June 30, 2026.
- →Cash flow is described as robust, with no issues in receivables and a strong free cash flow generation of INR90 crores in Q1 FY '27.
- →The company appears to be funding its capex (expected INR540 crores in FY '27) through internal accruals without requiring external debt or equity.
- →The focus is on operational discipline and steady growth, indicating no immediate need for fundraising via debt or equity.
Order book
Yes- →Alivus Life Sciences is actively engaged in about 7 ongoing CDMO projects.
- →Revenue currently comes from 5 existing projects.
- →There are new inquiries beyond these 7 projects, indicating a steady flow of potential business.
- →The CDMO segment is expected to accelerate growth in H2 FY '27 and continue expanding in FY '28 with new projects kicking in.
- →The company is confident of maintaining steady demand and growth from its existing pipeline and new launches.
- →The robust product pipeline includes 29 active high-potent API products with a total addressable market of $82 billion.
- →The Solapur facility is being readied to increase capacity and contribute to order fulfillment once regulatory approvals are completed.
- →Overall, Alivus expects orderbook growth driven by new launches, lifecycle management, and specialty CDMO projects.
Capex plans
Yes- →Capex for Q1 FY '27 was INR85 crores; expected capex for FY '27 is approximately INR540 crores.
- →Priority capex focus remains on completion of expansions at Dahej (160KL increase) and Ankleshwar (110KL increase), both on track.
- →Solapur Phase 1 and 1.1 nearing completion, to be operational by Q3 FY '27, with inspections planned within a year post-operation for regulatory approvals.
- →Solapur expansion (Phase 3) has been delayed by about a year to avoid under-absorption and is planned as a greenfield project.
- →New R&D center construction at Taloja has begun and is progressing on schedule.
- →Investment focus on new API launches and improving manufacturing capabilities, especially for regulated markets.
- →Strategic investments targeted at synergistic acquisitions focusing on pipeline expansion rather than merely facility acquisition.
- →Overall, capex and strategic investments are calibrated to support double-digit growth while maintaining operational efficiency.
How does Alivus Life rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Alivus Life
Rev 3Mar 2
See full Pharmaceuticals & Biotechnology sector rankings
How does Alivus Life rank in Pharmaceuticals & Biotechnology?
Compare Alivus Life against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.